{"success":true,"data":{"pressRelease":{"id":"181409","rtpr_id":"nGNX70cpcl-20261027","ticker":"DOCS","exchange":"NYSE","all_tickers":["DOCS"],"title":"SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of November 16, 2026 in Doximity, Inc. Lawsuit - DOCS","author":"Globe Newswire","published_at":"2026-10-27T14:12:00.153Z","article_body":"NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- SueWallSt notifies investors in\nDoximity, Inc. (NYSE: DOCS) that a securities class action has been filed on\nbehalf of shareholders who purchased common stock between August 8, 2024 and\nMay 13, 2026. Find out if you might qualify for recovery\n(https://www.globenewswire.com/Tracker?data=-ir6rqMOlvAQdDxURaC-XdRQVMcKb84Fq8sgzthRtHdO5JPnrg8uXef313zPbypOaYrMJz3Mk9oRMLV_fOFi8odm3NB7JD9hq2kEO3huFid4VAqqbqh24cUcOofXOQxQA3CFw1lxMOgkZ2L_SKgkOS46gwozO7i0jdYBdKaEAgvgdizFxq6I2E7E0mFOjoHneQroftbEyrEyHaP0Tx_onw==).\nYou may also contact Joseph E. Levi, Esq. at jlevi@SueWallSt.com or (888)\nSueWallSt.\n\nDOCS holders absorbed three separate declines totaling $19.26 per share: $8.29\n(13%) on November 7, 2025, $5.59 (17%) on February 6, 2026, and $5.38 (23%) on\nMay 14, 2026, the last carrying the stock from $23.39 to $18.01. Motions for\nlead plaintiff appointment must be filed by November 16, 2026.\n\nWhat the Company Disclosed\n\nDoximity measured itself largely with figures of its own construction. SEC\nfilings and quarterly calls reported \"record engagement,\" more than 1 million\nquarterly active prescribers, and double-digit growth in \"articles read or\ntapped,\" while revenue was billed through a proprietary \"cost-per-target\"\nstructure under which customers subscribe to modules to reach a set number of\nmembers each month. Company marketing materials accessible throughout the\nclass period stated that Doximity does not \"bombard physicians with ads and\nmessages in hopes of getting lucky.\"\n\nWhat Plaintiffs Allege Was Missing\n\nThe complaint challenges whether those company-defined figures told\nshareholders anything about the commercial trends that actually governed\ngrowth.\n\nDisclosure Gaps Alleged\n* Engagement counts were allegedly reported without the corresponding revenue\ncontribution, overstating the Newsfeed's impact on sales growth\n* No disclosure that older advertising formats were allegedly losing share\nwhile programmatic and social formats gained, a dynamic Evercore described\nafter February 5, 2026\n* Alleged reliance on banner ads and email newsletters, methods the Company's\nown materials disclaimed\n* Net revenue retention, later characterized by RBC Capital Markets as stalled\nin an \"increasingly competitive market,\" allegedly not framed as a\ndeteriorating indicator\n* A shift in which pharmaceutical customers deployed lower percentages of\ntheir budgets upfront, a pattern discussed only after fiscal 2026 guidance was\nreduced\nWhy Generic Warnings May Not Protect\n\nDisclosure language indicated confidence in competitive position and\nengagement quality. The action contends that boilerplate cautionary wording\ndid not cure the omission of specific, already-developing pressures on\npharmaceutical ad budgets, and that investors bought at prices reflecting the\nfavorable figures rather than the underlying trend.\n\n\"Generic risk factor language cannot substitute for disclosing specific, known\nproblems that are already affecting a company's operations. Here the action\nasserts Doximity continued reporting record engagement metrics while its share\nof pharmaceutical advertising spend was allegedly eroding.\" -- Joseph E. Levi,\nEsq.\n\nSubmit your information now\n(https://www.globenewswire.com/Tracker?data=3UuTsn02ewfF9wIiot-P8fXUdSomTvUNxq38xHODFh4FSNG5BQcGFW3Tq8bUmRs-R6xIcSea9_IhE3CisnkMfWY2NHfFA_nBKpeWzeaNvhFdK3y9720Qz8rP4HZCNdeM3XT707lojdnc30Us2CowRVb-Ri-Xy_ud1WLHxRT8A3ivsWURWLUmVVNd08dWuVLh)\nor call (888) SueWallSt.\n\nWHY SUEWALLST: SueWallSt is powered by Levi & Korsinsky LLP. Levi & Korsinsky\nLLP has established itself as a nationally-recognized securities litigation\nfirm that has secured hundreds of millions of dollars for aggrieved\nshareholders and built a track record of winning high-stakes cases. The firm\nhas extensive expertise representing investors in complex securities\nlitigation and a team of over 70 employees to serve our clients. For seven\nyears in a row, Levi & Korsinsky has ranked in ISS Securities Class Action\nServices' Top 50 Report as one of the top securities litigation firms in the\nUnited States.\n\nFrequently Asked Questions About the DOCS Lawsuit\n\nQ: When did Doximity allegedly mislead investors? A: The Class Period runs\nfrom August 8, 2024 to May 13, 2026. The complaint alleges that multiple\ncorrective disclosures events revealed information that caused significant\nstock declines.\n\nQ: What court was the DOCS class action filed in? A: The case was filed in the\nUnited States District Court for the Northern District of California, governed\nby the Private Securities Litigation Reform Act of 1995.\n\nQ: Who are the defendants named in the DOCS lawsuit? A: The complaint names\nDoximity, Inc. and a set of individual defendants who held senior positions at\nthe company for all or part of the Class Period, including co-founder, CEO,\nand Chairman Jeffrey Tangney, CFO Anna Bryson, co-founder and Chief Strategy\nOfficer Nate Gross, and VP of Investor Relations & Revenue Operations, Perry\nGold.\n\nQ: What do DOCS investors need to do right now? A: Investors may gather\nbrokerage records showing purchase dates, share quantities, and prices paid.\nSubmit your information for a no-cost, no-obligation evaluation of your\npotential recovery\n(https://www.globenewswire.com/Tracker?data=3UuTsn02ewfF9wIiot-P8fXUdSomTvUNxq38xHODFh4J-wYZ4wHlfxYQv8W1K6886T8LSPTIcrrKyVMQUkBvc3P74sjMetA6a_PLBYSUjExb7zpk5gmk6UFqplAhnZeZNspNceD46YsxM5v-8-7F8k6d-90_SFKjXyMtK5tKDZJWal3_MHK9kvdsIYMEqozonuCmowx2tacHT2GD0dPOxLPFmKOlQNa-th0lp0r42Riw4aAwvpi5dLDWYVmGkqCSc-AgM3ZgWWgBHOGSkww8IQ==).\nNo immediate action is required to remain eligible as an absent class member.\n\nQ: What happens after I submit my information? A: Your trading history will be\nreviewed at no cost for an initial assessment of your potential eligibility.\n\nQ: Do I need to go to court or give testimony? A: No. The overwhelming\nmajority of class members never appear in court or give depositions. If there\nis a settlement or recovery, eligible class members generally submit a claim\nform to seek their portion.\n\nQ: Can I join a different law firm's lawsuit instead? A: Yes. Investors may\nchoose which law firm to contact. Multiple firms often file competing\ncomplaints. The court may consolidate related cases and appoint a single lead\ncounsel.\n\nQ: What if I live outside the United States? A: U.S. securities class actions\ngenerally cover purchases on U.S. exchanges regardless of the investor's\ncountry of residence.\n\nCONTACT:\nLevi & Korsinsky, LLP\nJoseph E. Levi, Esq.\n33 Whitehall Street, 27th Floor\nNew York, NY 10004\njlevi@SueWallSt.com\nTel: (888) SueWallSt\nFax: (212) 363-7171\n\nAttorney Advertising. Prior results do not guarantee similar outcomes.\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX70cpcl-20261027","title":"SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of November 16, 2026 in Doximity, Inc. Lawsuit - DOCS","author":"Globe Newswire","ticker":"DOCS","created":"2026-10-27T14:12:00.153Z","tickers":["DOCS"],"exchange":"NYSE","article_body":"NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- SueWallSt notifies investors in\nDoximity, Inc. (NYSE: DOCS) that a securities class action has been filed on\nbehalf of shareholders who purchased common stock between August 8, 2024 and\nMay 13, 2026. Find out if you might qualify for recovery\n(https://www.globenewswire.com/Tracker?data=-ir6rqMOlvAQdDxURaC-XdRQVMcKb84Fq8sgzthRtHdO5JPnrg8uXef313zPbypOaYrMJz3Mk9oRMLV_fOFi8odm3NB7JD9hq2kEO3huFid4VAqqbqh24cUcOofXOQxQA3CFw1lxMOgkZ2L_SKgkOS46gwozO7i0jdYBdKaEAgvgdizFxq6I2E7E0mFOjoHneQroftbEyrEyHaP0Tx_onw==).\nYou may also contact Joseph E. Levi, Esq. at jlevi@SueWallSt.com or (888)\nSueWallSt.\n\nDOCS holders absorbed three separate declines totaling $19.26 per share: $8.29\n(13%) on November 7, 2025, $5.59 (17%) on February 6, 2026, and $5.38 (23%) on\nMay 14, 2026, the last carrying the stock from $23.39 to $18.01. Motions for\nlead plaintiff appointment must be filed by November 16, 2026.\n\nWhat the Company Disclosed\n\nDoximity measured itself largely with figures of its own construction. SEC\nfilings and quarterly calls reported \"record engagement,\" more than 1 million\nquarterly active prescribers, and double-digit growth in \"articles read or\ntapped,\" while revenue was billed through a proprietary \"cost-per-target\"\nstructure under which customers subscribe to modules to reach a set number of\nmembers each month. Company marketing materials accessible throughout the\nclass period stated that Doximity does not \"bombard physicians with ads and\nmessages in hopes of getting lucky.\"\n\nWhat Plaintiffs Allege Was Missing\n\nThe complaint challenges whether those company-defined figures told\nshareholders anything about the commercial trends that actually governed\ngrowth.\n\nDisclosure Gaps Alleged\n* Engagement counts were allegedly reported without the corresponding revenue\ncontribution, overstating the Newsfeed's impact on sales growth\n* No disclosure that older advertising formats were allegedly losing share\nwhile programmatic and social formats gained, a dynamic Evercore described\nafter February 5, 2026\n* Alleged reliance on banner ads and email newsletters, methods the Company's\nown materials disclaimed\n* Net revenue retention, later characterized by RBC Capital Markets as stalled\nin an \"increasingly competitive market,\" allegedly not framed as a\ndeteriorating indicator\n* A shift in which pharmaceutical customers deployed lower percentages of\ntheir budgets upfront, a pattern discussed only after fiscal 2026 guidance was\nreduced\nWhy Generic Warnings May Not Protect\n\nDisclosure language indicated confidence in competitive position and\nengagement quality. The action contends that boilerplate cautionary wording\ndid not cure the omission of specific, already-developing pressures on\npharmaceutical ad budgets, and that investors bought at prices reflecting the\nfavorable figures rather than the underlying trend.\n\n\"Generic risk factor language cannot substitute for disclosing specific, known\nproblems that are already affecting a company's operations. Here the action\nasserts Doximity continued reporting record engagement metrics while its share\nof pharmaceutical advertising spend was allegedly eroding.\" -- Joseph E. Levi,\nEsq.\n\nSubmit your information now\n(https://www.globenewswire.com/Tracker?data=3UuTsn02ewfF9wIiot-P8fXUdSomTvUNxq38xHODFh4FSNG5BQcGFW3Tq8bUmRs-R6xIcSea9_IhE3CisnkMfWY2NHfFA_nBKpeWzeaNvhFdK3y9720Qz8rP4HZCNdeM3XT707lojdnc30Us2CowRVb-Ri-Xy_ud1WLHxRT8A3ivsWURWLUmVVNd08dWuVLh)\nor call (888) SueWallSt.\n\nWHY SUEWALLST: SueWallSt is powered by Levi & Korsinsky LLP. Levi & Korsinsky\nLLP has established itself as a nationally-recognized securities litigation\nfirm that has secured hundreds of millions of dollars for aggrieved\nshareholders and built a track record of winning high-stakes cases. The firm\nhas extensive expertise representing investors in complex securities\nlitigation and a team of over 70 employees to serve our clients. For seven\nyears in a row, Levi & Korsinsky has ranked in ISS Securities Class Action\nServices' Top 50 Report as one of the top securities litigation firms in the\nUnited States.\n\nFrequently Asked Questions About the DOCS Lawsuit\n\nQ: When did Doximity allegedly mislead investors? A: The Class Period runs\nfrom August 8, 2024 to May 13, 2026. The complaint alleges that multiple\ncorrective disclosures events revealed information that caused significant\nstock declines.\n\nQ: What court was the DOCS class action filed in? A: The case was filed in the\nUnited States District Court for the Northern District of California, governed\nby the Private Securities Litigation Reform Act of 1995.\n\nQ: Who are the defendants named in the DOCS lawsuit? A: The complaint names\nDoximity, Inc. and a set of individual defendants who held senior positions at\nthe company for all or part of the Class Period, including co-founder, CEO,\nand Chairman Jeffrey Tangney, CFO Anna Bryson, co-founder and Chief Strategy\nOfficer Nate Gross, and VP of Investor Relations & Revenue Operations, Perry\nGold.\n\nQ: What do DOCS investors need to do right now? A: Investors may gather\nbrokerage records showing purchase dates, share quantities, and prices paid.\nSubmit your information for a no-cost, no-obligation evaluation of your\npotential recovery\n(https://www.globenewswire.com/Tracker?data=3UuTsn02ewfF9wIiot-P8fXUdSomTvUNxq38xHODFh4J-wYZ4wHlfxYQv8W1K6886T8LSPTIcrrKyVMQUkBvc3P74sjMetA6a_PLBYSUjExb7zpk5gmk6UFqplAhnZeZNspNceD46YsxM5v-8-7F8k6d-90_SFKjXyMtK5tKDZJWal3_MHK9kvdsIYMEqozonuCmowx2tacHT2GD0dPOxLPFmKOlQNa-th0lp0r42Riw4aAwvpi5dLDWYVmGkqCSc-AgM3ZgWWgBHOGSkww8IQ==).\nNo immediate action is required to remain eligible as an absent class member.\n\nQ: What happens after I submit my information? A: Your trading history will be\nreviewed at no cost for an initial assessment of your potential eligibility.\n\nQ: Do I need to go to court or give testimony? A: No. The overwhelming\nmajority of class members never appear in court or give depositions. If there\nis a settlement or recovery, eligible class members generally submit a claim\nform to seek their portion.\n\nQ: Can I join a different law firm's lawsuit instead? A: Yes. Investors may\nchoose which law firm to contact. Multiple firms often file competing\ncomplaints. The court may consolidate related cases and appoint a single lead\ncounsel.\n\nQ: What if I live outside the United States? A: U.S. securities class actions\ngenerally cover purchases on U.S. exchanges regardless of the investor's\ncountry of residence.\n\nCONTACT:\nLevi & Korsinsky, LLP\nJoseph E. Levi, Esq.\n33 Whitehall Street, 27th Floor\nNew York, NY 10004\njlevi@SueWallSt.com\nTel: (888) SueWallSt\nFax: (212) 363-7171\n\nAttorney Advertising. Prior results do not guarantee similar outcomes.\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-27T14:12:00.190858241Z","server_sent_at_ms":1793110320190},"received_at":"2026-10-27T14:12:00.338Z","source_url":null},"analysis":{"id":"169213","press_release_id":"181409","analysis_json":{"industry":{"label":"Health Care Providers & Services","sector":"Health Care"},"redFlags":["active securities class action against Doximity naming CEO Jeffrey Tangney and CFO Anna Bryson as defendants","alleged disclosure gaps around engagement metrics, net revenue retention, and pharma ad-budget shifts"],"eventType":"legal_litigation","narrative":"SueWallSt, powered by Levi & Korsinsky LLP, issued a reminder to Doximity (DOCS) investors of a November 16, 2026 lead-plaintiff deadline in a securities class action covering purchases between August 8, 2024 and May 13, 2026.\n\nThe underlying complaint alleges Doximity overstated engagement metrics while its share of pharmaceutical advertising spend eroded, with three corrective-disclosure declines totaling $19.26 per share during the class period.\n\nThis is a plaintiff-firm solicitation, not a new company disclosure or court action; treat as low-signal noise for the stock.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress."},"keyFigures":{"customDimensions":{"class_period_end":"May 13, 2026","class_period_start":"August 8, 2024","lead_plaintiff_deadline":"November 16, 2026"}},"quotedText":"Generic risk factor language cannot substitute for disclosing specific, known problems that are already affecting a company's operations.","namedEntities":{"people":[{"name":"Joseph E. Levi, Esq.","role":"partner, Levi & Korsinsky LLP"},{"name":"Jeffrey Tangney","role":"co-founder, CEO and Chairman of Doximity (defendant)"},{"name":"Anna Bryson","role":"CFO of Doximity (defendant)"},{"name":"Nate Gross","role":"co-founder and Chief Strategy Officer of Doximity (defendant)"},{"name":"Perry Gold","role":"VP of Investor Relations & Revenue Operations at Doximity (defendant)"}],"products":[],"companies":[{"name":"SueWallSt / Levi & Korsinsky LLP","relationship":"plaintiff law firm"},{"name":"Doximity, Inc.","ticker":"DOCS","relationship":"issuer / defendant"},{"name":"Evercore","relationship":"analyst firm cited"},{"name":"RBC Capital Markets","relationship":"analyst firm cited"}],"dollarAmounts":[{"amount":"$19.26 per share","context":"cumulative stock declines alleged during class period"},{"amount":"$8.29","context":"decline on November 7, 2025"},{"amount":"$5.59","context":"decline on February 6, 2026"},{"amount":"$5.38","context":"decline on May 14, 2026"},{"amount":"$23.39","context":"stock price before May 14, 2026 decline"},{"amount":"$18.01","context":"stock price after May 14, 2026 decline"}]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm solicitation (Levi & Korsinsky / SueWallSt) reminding DOCS investors of a lead plaintiff deadline in an already-filed securities class action. No issuer disclosure, no certified class, no settlement."},"tickerRelevance":{"others":[],"primary":"DOCS"},"globalImportance":15,"audienceRelevance":20,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false,"retailFavoriteBoost":"DOCS has some retail following, modest lift"}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"SueWallSt, powered by Levi & Korsinsky LLP, issued a reminder to Doximity (DOCS) investors of a November 16, 2026 lead-plaintiff deadline in a securities class action covering purchases between August 8, 2024 and May 13, 2026.\n\nThe underlying complaint alleges Doximity overstated engagement metrics while its share of pharmaceutical advertising spend eroded, with three corrective-disclosure declines totaling $19.26 per share during the class period.\n\nThis is a plaintiff-firm solicitation, not a new company disclosure or court action; treat as low-signal noise for the stock.","key_figures":{"customDimensions":{"class_period_end":"May 13, 2026","class_period_start":"August 8, 2024","lead_plaintiff_deadline":"November 16, 2026"}},"named_entities":{"people":[{"name":"Joseph E. Levi, Esq.","role":"partner, Levi & Korsinsky LLP"},{"name":"Jeffrey Tangney","role":"co-founder, CEO and Chairman of Doximity (defendant)"},{"name":"Anna Bryson","role":"CFO of Doximity (defendant)"},{"name":"Nate Gross","role":"co-founder and Chief Strategy Officer of Doximity (defendant)"},{"name":"Perry Gold","role":"VP of Investor Relations & Revenue Operations at Doximity (defendant)"}],"products":[],"companies":[{"name":"SueWallSt / Levi & Korsinsky LLP","relationship":"plaintiff law firm"},{"name":"Doximity, Inc.","ticker":"DOCS","relationship":"issuer / defendant"},{"name":"Evercore","relationship":"analyst firm cited"},{"name":"RBC Capital Markets","relationship":"analyst firm cited"}],"dollarAmounts":[{"amount":"$19.26 per share","context":"cumulative stock declines alleged during class period"},{"amount":"$8.29","context":"decline on November 7, 2025"},{"amount":"$5.59","context":"decline on February 6, 2026"},{"amount":"$5.38","context":"decline on May 14, 2026"},{"amount":"$23.39","context":"stock price before May 14, 2026 decline"},{"amount":"$18.01","context":"stock price after May 14, 2026 decline"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-27T14:12:06.300Z","global_importance":15,"audience_relevance":20,"importance_components":{"tickerTier":"mid-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false,"retailFavoriteBoost":"DOCS has some retail following, modest lift"}},"durationMs":5779,"modelName":"glm-5.3-flashx"}}